{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:50Z","timestamp":1793176790326,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T03:03:17Z","timestamp":1704855797000},"page":"483-490.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8302-2173","authenticated-orcid":false,"given":"Obaid Ur","family":"Rehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ali","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeshal","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.01.003_bib0001","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/biomedicines10030689","article-title":"Definition of castrate resistant prostate cancer: new insights","volume":"10","author":"Morote","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.003_bib0002","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5489\/cuaj.10167","article-title":"Guidelines for the management of castrate-resistant prostate cancer","volume":"4","author":"Saad","year":"2010","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2024.01.003_bib0003","series-title":"Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-99286-0_7","article-title":"Castration-resistant prostate cancer: mechanisms, targets and treatment. Molecular & Diagnostic Imaging in Prostate Cancer","author":"Mansinho","year":"2018"},{"issue":"10","key":"10.1016\/j.clgc.2024.01.003_bib0004","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-018-0077-y","article-title":"The role of ketoconazole in current prostate cancer care","volume":"15","author":"Patel","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2024.01.003_sbref0005","series-title":"Critical Appraisal Tools","year":"2021"},{"key":"10.1016\/j.clgc.2024.01.003_bib0006","unstructured":"NHLBI, NIH Study Quality Assessment Tools | [Internet]. NHLBI, NIH. [cited 2023 Oct 20]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"issue":"4","key":"10.1016\/j.clgc.2024.01.003_bib0007","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-5347(01)64924-3","article-title":"Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal","volume":"157","author":"Small","year":"1997","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.003_bib0008","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1994.12.4.683","article-title":"Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer","volume":"12","author":"Sella","year":"1994","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.003_bib0009","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1097\/01.ju.0000158449.83022.40","article-title":"Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone","volume":"173","author":"Scholz","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.003_bib0010","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.juro.2007.08.011","article-title":"Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome","volume":"178","author":"Ryan","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.003_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1464-410X.2010.09825.x","article-title":"Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration","volume":"108","author":"Procopio","year":"2011","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.003_bib0012","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/cncr.22085","article-title":"Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer","volume":"107","author":"Nakabayashi","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.003_bib0013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/pcan.2015.2","article-title":"Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients","volume":"18","author":"Lo","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.003_bib0014","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/aja.2012.57","article-title":"The prognostic factors of effective ketoconazole treatment for metastatic castration-resistant prostate cancer: who can benefit from ketoconazole therapy?","volume":"14","author":"Lin","year":"2012","journal-title":"Asian J Androl"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.003_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pros.21447","article-title":"Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression","volume":"72","author":"Keizman","year":"2012","journal-title":"Prostate"},{"issue":"12","key":"10.1016\/j.clgc.2024.01.003_bib0016","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2012-0125","article-title":"Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram","volume":"17","author":"Keizman","year":"2012","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.003_bib0017","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","article-title":"Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer","volume":"168","author":"Harris","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.003_bib0018","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdp199","article-title":"Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer","volume":"20","author":"Galsky","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.003_bib0019","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.juro.2010.02.020","article-title":"A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer","volume":"183","author":"Figg","year":"2010","journal-title":"J Urology"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.003_bib0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/01.ju.0000147013.09157.8e","article-title":"A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases","volume":"173","author":"Figg","year":"2005","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.003_bib0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.urols.2012.04.004","article-title":"Ketoconazole in Taiwanese castration-resistant prostate cancer patients: evaluation of response rates, durations, and predictors","volume":"23","author":"Chiang","year":"2012","journal-title":"Urol Sci"},{"issue":"6","key":"10.1016\/j.clgc.2024.01.003_bib0022","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10637-018-0660-3","article-title":"Ketoconazole plus Lenalidomide in patients with castration-resistant prostate cancer (CRPC): results of an open-label phase II study","volume":"36","author":"Barata","year":"2018","journal-title":"Invest New Drugs"},{"issue":"10","key":"10.1016\/j.clgc.2024.01.003_bib0023","doi-asserted-by":"crossref","first-page":"811","DOI":"10.47102\/annals-acadmedsg.V36N10p811","article-title":"Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and the Cancer Institute, Singapore","volume":"36","author":"Ngo","year":"2007","journal-title":"Ann Acad Med Singap"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.003_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2298\/ACI0504051A","article-title":"An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer","volume":"52","author":"Argirovic","year":"2005","journal-title":"Acta Chir Iugosl"},{"issue":"3","key":"10.1016\/j.clgc.2024.01.003_bib0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/07357907.2013.764564","article-title":"Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments","volume":"31","author":"Amato","year":"2013","journal-title":"Cancer Investig"},{"issue":"2","key":"10.1016\/j.clgc.2024.01.003_bib0026","first-page":"52","article-title":"Efficacy of ketoconazole in hormone refractory prostate cancer patients","volume":"10","author":"Akhtar","year":"2009","journal-title":"J Med"},{"issue":"11","key":"10.1016\/j.clgc.2024.01.003_bib0027","doi-asserted-by":"crossref","first-page":"746","DOI":"10.4111\/kju.2011.52.11.746","article-title":"Comparison of ketoconazole and estramustine for treating patients with castration-resistant prostate cancer","volume":"52","author":"Yun","year":"2011","journal-title":"Korean J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.003_bib0028","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2003.11.031","article-title":"An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer","volume":"45","author":"Wilkinson","year":"2004","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.clgc.2024.01.003_bib0029","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/1078-0432.CCR-09-1722","article-title":"Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer","volume":"15","author":"Taplin","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.01.003_bib0030","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2024.01.003_bib0031","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/COC.0000000000000660","article-title":"Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"43","author":"Liu","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.01.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2020.101833","article-title":"Epidemiology of metastatic castration-resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database","volume":"69","author":"Thurin","year":"2020","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"10.1016\/j.clgc.2024.01.003_bib0033","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.31557\/APJCP.2021.22.10.3101","article-title":"Ketoconazole for the treatment of docetaxel-na\u00efve metastatic castration-resistant prostate cancer (MCRPC): a systematic review","volume":"22","author":"Tresnanda","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.clgc.2024.01.003_bib0034","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4103\/jcrt.JCRT_295_18","article-title":"CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: a meta-analysis of published trials","volume":"16","author":"Cao","year":"2020","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.clgc.2024.01.003_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2016.02.013","article-title":"Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials","volume":"101","author":"Roviello","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"44","key":"10.1016\/j.clgc.2024.01.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017748","article-title":"Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"98","author":"Zheng","year":"2019","journal-title":"Medicine"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:27:51Z","timestamp":1793176071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767324000053"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}